Deriphylline

# Deriphylline ## Overview - **Classification**: Xanthine bronchodilator (combination of Etofylline and Theophylline) - **Mechanism**: Relaxes bronchial smooth muscle by inhibiting phosphodiesterase, leading to increased cyclic AMP. It also has mild anti-inflammatory effects and improves diaphragmatic contractility. ## Primary Indications 1. **Bronchial Asthma** - Management of acute and chronic asthma exacerbations and maintenance. 2. **Chronic Obstructive Pulmonary Disease (COPD)** - Symptomatic relief of bronchospasm. 3. **Bronchitis** - To alleviate associated bronchospasm and improve airflow. ## Adult Dosing ### Standard Dosing **Maintenance of Bronchospasm** - **Dose**: Typically **1-2 tablets** of common strength (e.g., 200 mg Etofylline + 64 mg Theophylline) - **Frequency**: **Twice daily** (every 12 hours) - **Route**: **Oral** - **Duration**: Chronic as required for symptom control. **Acute Exacerbation (Intravenous)** - **Dose**: Loading dose: **5-6 mg/kg** (Theophylline equivalent) IV over 20-30 minutes. - **Frequency**: Followed by maintenance infusion (e.g., **0.5-0.9 mg/kg/hr**). - **Route**: **Intravenous (IV)** - **Special Consideration**: Use ideal body weight for dosing. Only if patient has not received xanthines in last 24 hrs. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment for mild-moderate. Monitor closely in severe impairment (CrCl < 10 mL/min). - **Hepatic Impairment**: Clearance significantly reduced. Reduce dose by **25-50%**; monitor serum levels closely. Avoid in severe liver disease. - **Elderly Patients**: Start with lower doses (e.g., **half the usual adult dose**) due to decreased clearance. Titrate cautiously, monitor for toxicity. ## Pediatric Dosing *Note: Dosing must be carefully individualized. Therapeutic drug monitoring (Theophylline levels) is crucial.* ### Neonates (0-28 days) - **Dose**: **Contraindicated** for routine use due to immature metabolism. - **Special Notes**: Only in exceptional circumstances for apnea of prematurity under strict supervision and TDM. ### Infants (1-12 months) - **Dose**: Initial: **4-5 mg/kg/day** (total theophylline equivalent). - **Frequency**: Divided every **6-8 hours**. - **Maximum**: Do not exceed **12 mg/kg/day**. - **Special Notes**: Syrup formulation. Start low, titrate based on serum levels. ### Children (1-12 years) - **Dose**: Initial: **5-6 mg/kg/day** (total theophylline equivalent). - **Frequency**: Divided every **6-8 hours**. - **Maximum**: Up to **16 mg/kg/day** (max 400 mg/day total xanthine). - **Special Notes**: Clearance is fastest in this age group, monitor serum levels closely. ### Adolescents (13-18 years) - **Dose**: Transition to adult dosing; typically **300-600 mg/day** (total xanthine). - **Frequency**: Divided into **2-3 doses**. - **Maximum**: **600 mg/day** or **10 mg/kg/day**, whichever is less. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to xanthines. - **Absolute**: Acute myocardial infarction, unstable angina. - **Absolute**: Active peptic ulcer disease. - **Absolute**: Uncontrolled seizure disorders. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, headache, restlessness, insomnia. - **Common (1-10%)**: Tremor, palpitations, dizziness, abdominal pain, diarrhea. - **Serious but Rare**: Seizures, cardiac arrhythmias (e.g., tachycardia, ventricular fibrillation), severe hypotension. Often associated with high serum levels. ### Key Drug Interactions - **CYP1A2 Inhibitors (e.g., Cimetidine, Erythromycin, Fluoroquinolones)**: **Increase** theophylline levels; **reduce Deriphylline dose**. - **CYP1A2 Inducers (e.g., Phenobarbital, Phenytoin, Rifampin)**: **Decrease** theophylline levels; **increase Deriphylline dose**. - **Beta-blockers (non-selective)**: May reduce bronchodilating effect. - **Furosemide**: May **increase** serum theophylline levels; monitor for toxicity. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG (if cardiac risk factors), liver and renal function tests. - **During Treatment**: * **Therapeutic Drug Monitoring (TDM)**: Serum theophylline levels **10-20 mcg/mL** is target range. * **Frequency**: Peak levels 1-2 hours post oral dose, or 30 min post IV loading; trough levels just before next dose. * **Clinical Signs**: Monitor for improved respiratory function and signs of toxicity (e.g., nausea, tremors, palpitations, agitation). ## Clinical Pearls - 💡 **Tip 1**: Always monitor serum theophylline levels due to its narrow therapeutic index and significant inter-patient variability. - 💡 **Tip 2**: Smoking increases theophylline clearance; smokers often need higher doses. Cessation requires dose reduction. - 💡 **Tip 3**: Administer with food or after meals to minimize gastrointestinal upset. - 💡 **Tip 4**: Avoid excessive caffeine intake as it can exacerbate adverse effects like jitters and palpitations. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.